Nonclinical Safety Assessment of Next Generation Biologicals: NanobodiesⓇ
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
S Jacobs, S De Boever, MP Bouche…
… Primate Research in …, 2012
books.google.com
Nanobodies® are a novel class of therapeutic proteins based on the smallest functional fragments of heavy-chain antibodies, naturally occurring in Camelidae. They are developed for a wide range of disease indications including haematology, inflammation, oncology, and pulmonary disease. Ablynx has approximately 25 Nanobody programmes (both partnered and wholly-owned) in its product pipeline, and seven Nanobodies have entered clinical development (status: first half of 2012). The first Nanobody achieved clinical proof-of …
